Navigation Links
ARIUS announces first quarter fiscal 2008 financial results
Date:4/11/2008

nd cash equivalents,

end of period 9,760,273 4,824,896 9,760,273

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking

statements" within the meaning of the Private Securities Litigation

Reform Act of 1995, which involve known and unknown risks, uncertainties

and other factors that may cause our actual results to be materially

different from any future results, performance or achievements expressed

or implied by such statements. Forward-looking statements in this release

include, but are not limited to, ARIUS successfully advancing its new

product programs as well as licensing opportunities. These statements are

only predictions and actual events or results may differ materially.

Factors that could cause such actual events or results expressed or

implied by such forward-looking statements to differ materially from any

future results expressed or implied by such statements include, but are

not limited to: early stage of development; technology and product

development; dependence on and management of current and future corporate

collaborations; future capital needs; uncertainty of additional funding;

no assurance of market acceptance; dependence on proprietary technology

and uncertainty of patent protection; intense competition; manufacturing

and market uncertainties; and government regulation. These and other

factors are described in detail in ARIUS' Annual Report, forthcoming news

releases and other filings with Canadian securities regulatory

authorities available at http://www.sedar.com. Forward-looking statements are

based on our current expectat
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
2. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
3. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
4. ARIUS to present at Chinese Global Financial Forum
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
8. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
9. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Texas , Dec. 16, 2014  Vermillion, Inc. ... focused on gynecologic disease, today announced the next step ... a premier bio-analytics solutions provider with the naming of ... President and Chief Executive Officer, while current Chairman of ... continue to serve as Chairman. These changes are effective ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
(Date:12/15/2014)... NEW YORK & PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI ), a leading ... announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. ... Israel,s Office of the Chief ... has been in receipt of grant support from the ...
(Date:12/15/2014)... 15, 2014  Origin Agritech Limited (NASDAQ GS: SEED) (" ... of crop seeds in China , today ... year 2014 ended September 30, 2014, before the market opens ... host a teleconference on January 8, 2015, at 8:00 a.m. ... to discuss the results. To participate in the call, please ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3
... Chairman of Audit committee, TUSTIN, Calif., Nov. 5 ... announced today Mr. Douglas MacLellan has been elected by,its ... Officer and Executive,Chairman effective immediately. Mr. Michael Boswell has ... former role as Chairman of AMDL,s,Audit committee and long-standing ...
... Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ) today ... & Renshaw 10th Annual Healthcare Conference on,Tuesday, November ... will be held at,the New York Palace Hotel ... about this conference, please visit:, http://www.rodmanandrenshaw.com/conferences?id=19 , ...
... Mich., Nov. 5 InfuSystem,Holdings, Inc. (OTC Bulletin Board: ... pumps and associated clinical services,today announced financial results ... ended September 30, 2008., Mr. Steve Watkins, ... a solid 14.5% increase in revenue for the ...
Cached Biology Technology:AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO 2AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO 3AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO 4InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 2InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 3InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 4InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 5InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 6InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 7InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 8InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 9InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 10InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 11
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
(Date:12/11/2014)...  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ... the best ways to treat it. For example, ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... Resveratrol, a compound in grapes, displays antioxidant and ... researchers at the UT Health Science Center San Antonio ... beneficial health effects. Resveratrol stimulates the expression of ... store fat, the team found. Adiponectin has a wide ...
... The bacterium which causes acne (Propionibacterium acnes) will be the ... Peter Lambert of Aston University. As well as acne, this ... is often ignored at diagnosis. Why are we not more ... length of stomach upsets and boost the immune system: , ...
... study that relates global energy use to economic growth, ... finds strong correlations between these two measures both among ... the study,s authors to infer that energy use limits ... in energy supply will be required to meet the ...
Cached Biology News:Grape ingredient resveratrol increases beneficial fat hormone 2Probiotics, prebiotics and biofuel-producing bacteria 2Study finds energy limits global economic growth 2
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
Active GST Protein...
Marmoset plasma and serum - various quantities available...
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Biology Products: